Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Compare to CAR-T cells generated with traditional CARs, Armored CAR-T cells express immune checkpoint receptors that are able to regulate immune checkpoint signaling. High expression of immune checkpoint ligand is an efficient way for tumor cells to escape immune surveillance. This immune escape mechanism is also a major way for tumor cells to avoid adoptive T cell therapy. The tumor microenvironment contributes significantly to tumor development by inhibiting immune responses.
CAR-T cell therapy has become a central approach in cancer treatment. The success of CAR-T cell treatment requires them to survive and expand in vivo. However, most tumors employ an immune evasion mechanism to escape the infused CAR-T cells, which results in the production of many inhibitory cytokines that prevent T-cell persistence and effector functions. Various methods, such as regulating the cell-cell signaling, administration of cytokines and infusion of new generation CAR-T cells, are used to tackle the immunosuppression effect of tumors. The Armored CAR-T cells that express an immune checkpoint switch receptor have an improved efficacy. For example, Armored CAR-T cells expressing dominant negative transforming growth factor-β type II receptor (DNRII) confer T cell resistance to tumor production. The T cells expressing hybrid receptors comprising exodomain IL-4 and endodomain IL-7 can be activated by IL-4, which is a tumour-generated suppressive cytokine. The programmed cell death protein 1 (PD1) monoclonal antibody has shown the ability to enhance the efficiency of CAR-T cells in preclinical models. These results indicate that both endogenous immune cells and engineered T cells are subject to tumor immune suppression by immune checkpoints. T cell therapy can incorporate different forms of immune checkpoint blockade to further enhance their efficacy.
As the leading biotech company that provides CAR-T cell therapy related services, Creative Biolabs has the most advanced technology and extensive experience and thus, is able to offer the best products and services. Here we present the SmarterTM Armored CAR construction service including the design and construction of CAR, virus packaging, T cell engineering and the in vitro and in vivo test of CAR-T cell therapy.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
